This is a Phase 1, double-blind, placebo-controlled study in approximately 32 healthy volunteers who are 18 to 55 years old. Four cohorts are planned, each consisting of 8 subjects; the cohorts as planned are 0.225, 0.75, 2.25, and 7.5 g in oral solution. Increasing doses of CDX-6114 will be assessed sequentially until the final dose is evaluated or any of the stopping criteria are reached. Subjects will each receive a single dose and then will be followed for a total of 22 days (3 weeks).
The purpose of this study is to assess the safety and tolerability of an oral solution of CDX-6114 when administered as a single dose in healthy volunteers.